Attralus wins FDA orphan drug status for AL amyloidosis candidate AT-02
Attralus has secured US FDA orphan drug designation for zamubafusp alfa (AT-02) in light chain (AL) amyloidosis, the Florida-based clinical-stage company announced on 4 June 2026.
The designation adds to three existing orphan recognitions — including a prior FDA grant for transthyretin-associated amyloidosis (ATTR) and two positive opinions from the European Medicines Agency's Committee for Orphan Medicinal Products covering both AL and ATTR subtypes.
Zamubafusp alfa is a humanised IgG1 monoclonal antibody fused with a proprietary pan-amyloid binding peptide. The mechanism is distinct from the current standard of care: rather than suppressing production of the misfolded protein upstream, the drug is designed to bind to amyloid deposits already lodged in organs and stimulate macrophage-mediated clearance. Attralus describes the approach as a pan-amyloid removal (PAR) therapeutic, positioning it as complementary to — or a follow-on from — haematologic induction regimens.
Unmet need and mechanism
AL amyloidosis affects an estimated 25,000 patients in the United States, with roughly 4,500 new diagnoses each year. The disease is driven by clonal plasma cells that secrete toxic light chains, which aggregate into amyloid fibrils and deposit in the heart, kidneys, and other organs. The combination of daratumumab, cyclophosphamide, bortezomib, and dexamethasone (dara-CyBorD) is the established first-line regimen and targets haematologic response. As Gregory Bell, Chief Medical Officer at Attralus, noted in the announcement: "There is a significant unmet need for new therapies that can remove existing toxic amyloid fibrils that cause organ damage and mortality." No therapy currently approved in the US or Europe directly targets amyloid removal.
Zamubafusp alfa has completed a Phase 1 study and is now in an ongoing Phase 2 open-label trial, both of which enrolled AL amyloidosis patients. Attralus has not yet disclosed efficacy readouts from either study publicly, and no timeline for Phase 2 data was given in the release.
Regulatory and competitive context
Orphan drug designation in the US confers meaningful development incentives: tax credits of up to 25% on qualifying clinical costs, waived FDA user fees, and seven years of post-approval marketing exclusivity. These benefits are particularly material for small patient populations where commercial returns are otherwise constrained, making the designation a de-risking signal for investors as well as a regulatory one.
The amyloid-removal space has attracted increasing attention over the past several years. CAEL-101, developed by Caelum Biosciences and later acquired by AstraZeneca, pursued a similar fibril-targeting strategy in AL amyloidosis before its Phase 2/3 programme was discontinued following negative results in 2023 — a cautionary precedent that will frame how clinicians and investors read Attralus's forthcoming Phase 2 data. Several academic groups and smaller biotechs continue to investigate complementary approaches, including serum amyloid P-directed strategies and small-molecule fibril disruptors, suggesting the therapeutic hypothesis retains scientific credibility even after the CAEL-101 setback.
For Attralus, the accumulation of four orphan designations across two regulatory jurisdictions and two amyloid subtypes signals a broadening regulatory strategy. The next material catalyst will be efficacy and safety data from the Phase 2 study, which is expected to inform both a potential registrational path and partnership discussions.